Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 17,574 shares, a decline of 48.6% from the October 15th total of 34,177 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily volume of 16,714 shares, the short-interest ratio is presently 1.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.00.
Read Our Latest Research Report on Alzamend Neuro
Alzamend Neuro Trading Down 2.5%
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last issued its quarterly earnings data on Thursday, September 10th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.12). On average, equities research analysts predict that Alzamend Neuro will post -1.05 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alzamend Neuro
An institutional investor recently raised its stake in Alzamend Neuro stock. Kingsbury Capital Investment Advisors LLC grew its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 134.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329,100 shares of the company’s stock after buying an additional 762,367 shares during the period. Alzamend Neuro makes up about 1.3% of Kingsbury Capital Investment Advisors LLC’s holdings, making the stock its 18th biggest holding. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 49.61% of the stock is currently owned by hedge funds and other institutional investors.
About Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease and other neuropsychiatric disorders. The company is based in the United States and does not have marketed products. Its pipeline includes AL001, an investigational lithium-based treatment being studied for conditions including Alzheimer’s disease and bipolar disorder, and ALZN002, an investigational cell-based immunotherapy designed to target Alzheimer’s disease. Both programs remain in development, and their safety and effectiveness have not been established.
Recommended Stories
- Five stocks we like better than Alzamend Neuro
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
